Brenda Carney
Family · New Hartford, NYNPI 1639333230
Payments from drug & device makers
Across 357 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- Novo Nordisk$860
- AstraZeneca$833
- Astellas Pharma US Inc$804
- Lilly USA, LLC$530
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,94197%
- Education$2433%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $1,035 |
| GSK | 42 | $1,019 |
| Novo Nordisk | 41 | $860 |
| AstraZeneca(2 entities) | 45 | $833 |
| Astellas Pharma US Inc | 37 | $804 |
| Lilly USA, LLC | 23 | $530 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $497 |
| Johnson & Johnson(2 entities) | 7 | $482 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $448 |
| Pfizer | 19 | $365 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $234 |
| Boehringer Ingelheim | 7 | $164 |
| Gilead | 4 | $151 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Exact Sciences | 4 | $68 |
| Bausch Health US, LLC | 4 | $66 |
| Mylan Specialty L.p. | 3 | $48 |
| Baxter Healthcare | 1 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $43 |
| Amgen | 2 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| Sun Pharmaceutical Industries Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Corium, LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| Merck | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$388
- XIFAXAN$253
- CAPLYTA$250
- TRELEGY ELLIPTA$125
- STELARA$125
- QULIPTA$125
- NURTEC ODT$125
- Ozempic$123
- ZEPBOUND$123
- Yeztugo$109
How this compares
$8,184 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $83,177 |
| EliquisApixaban | 38 | $51,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $37,742 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $35,094 |
| JanuviaSitagliptin Phosphate | 47 | $32,526 |
| JardianceEmpagliflozin | 16 | $24,374 |
| XareltoRivaroxaban | 11 | $16,731 |
| Acetazolamide ErAcetazolamide | 12 | $2,471 |
| Omeprazole | 184 | $2,450 |
| Rosuvastatin Calcium | 155 | $2,365 |
| Levothyroxine Sodium | 148 | $2,324 |
| Metoprolol Succinate | 88 | $2,112 |
| HyzaarLosartan/Hydrochlorothiazide | 11 | $1,930 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,693 |
| Losartan Potassium | 115 | $1,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $860 | $83,17766 claims |
| PfizerEliquis | $365 | $51,27838 claims |
| GSKTrelegy Ellipta | $1,019 | $37,74226 claims |
| AstraZenecaBreztri Aerosphere | $833 | $35,09436 claims |
| MerckJanuvia | $18 | $32,52647 claims |
| Boehringer IngelheimJardiance | $164 | $24,37416 claims |
| Johnson & JohnsonXarelto | $482 | $16,73111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in New Hartford
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.